ALK and non-small cell lung carcinoma: This is represented by the discovery of EML4-ALK fusion in ~ 4% of non-small cell lung cancer and FGFR-TACC fusion in ~ 3% of glioblastomas that have culminated in effective targeted therapies in these tumors [8, 9].